Mesoblast & Celgene..tick tock...., page-82

I remain very interested on the implications of the FDA review into stem cell related testing. To me this is crucial.

Because I signaled fast tracking for stem cell acceptances would be game changing and appropriate a considerable time ago, based on the model for safety and efficacy to pharmaceutical drugs (which have a range of unknown dangers and possible side effects) and which is at extreme end of rigour and even redundant, where for testing of stem cells applies.

This was much to your derision and that of fruitbat and another fly-by-nighter.

Quite obviously cutting down the recruitment numbers patients means getting to market much earlier with obvious implications for income.

It might be an opportunity for you to stop this game. I don't mind at all but you seem to.